Kornimate/medical-research-clean huggingface dataset:
registry of patients undergoing endoscopic management of pancreatic fluid collections

Conditions: Acute Pancreatitis; Pancreatic Pseudocyst; Pancreatic Necrosis

Summary: acute pancreatitis is one of the most common gastrointestinal disorders requiring hospitalization worldwide. pancreatic fluid collections can occur as a consequence of acute and chronic pancreatitis and can result in significant morbidity and mortality, including significant abdominal pain, gastric outlet obstruction, biliary obstruction, organ failure, persistent unwellness, infection and sepsis. symptomatic pancreatic fluid collections require treatment, and endoscopic drainage is considered standard of care. the aim of this study is to evaluate the treatment outcomes in patients undergoing standard of care, endoscopic treatment of pancreatic fluid collections.

acute pancreatitis has an annual incidence of 13-45 cases per 100,000 persons and is one of the most common gastrointestinal disorders requiring hospitalization worldwide. it leads to over a quarter of a million hospital admissions annually in the united states, and inpatient costs exceeding 2.5 billion us dollars. pancreatic fluid collections can occur as a consequence of acute and chronic pancreatitis and can result in significant morbidity and mortality, including significant abdominal pain, gastric outlet obstruction, biliary obstruction, organ failure, persistent unwellness, infection and sepsis. symptomatic pancreatic fluid collections require treatment, and endoscopic drainage is considered standard of care. endoscopic treatment involves the drainage of the fluid collection into the stomach or duodenum by placement of metal or plastic stents. if clinically indicated, endoscopic necrosectomy is also performed, which is the removal of devitalized pancreatic tissue using the endoscope. currently the treatment success rate of endoscopic treatment of pancreatic fluid collections exceeds 90%. the aim of this study is to evaluate the treatment outcomes in patients undergoing standard of care, endoscopic treatment of pancreatic fluid collections.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * all patients undergoing endoscopic treatment of pancreatic fluid collections exclusion criteria: * age \< 18 years * patients who did not receive endoscopic treatment of pancreatic fluid collections
meditation and exercise to treat chronic back pain

Conditions: Chronic Low Back Pain

Summary: this study evaluates the analgesic effect of a combination treatment of exercise and mindfulness based meditation in patients with chronic back pain. half of the participants will partake in a 4-week exercise and meditation intervention, while the other half will receive a placebo treatment. the investigators hypothesize that a combination treatment reduces disability and pain more than the control intervention.

exercise and mindfulness based mediation can both produce analgesic effects in patients with chronic pain, but the mechanisms are not clear. combining treatments could produce analgesic effects that are additive, synergistic, or counteractive to each other. here, the investigators examine the effects of a 4-week intervention in patients with chronic low back pain. patients are assigned to a meditation/exercise group or a control group. the investigators will measure pain and disability using a variety of tools including surveys (disability, anxiety, mindfulness, and pain), pain vas scales, and quantitative sensory testing.

Eligibility criteria:
inclusion criteria: 1. presence of clinically diagnosed nonspecific low back pain for at least 6 months 2. body mass index within the normal to overweight range (18.5-29.9) 3. resting heart rate 60 to 100 beats per minute 4. resting blood pressure less than or equal to 140/90 5. able to independently ambulate community distances without external support (e.g., walker, cane) exclusion criteria: 6. age less than 18 or greater than 60 years 7. bmi ≥ 30 or ≤ 18.4 8. cardiovascular or respiratory disease 9. neurological disease, unrelated to low back pain 10. radicular low back pain 11. back pain associated with neuropathy 12. diabetes mellitus, types 1 and 2 13. diagnosed with a chronic pain condition, unrelated to low back pain 14. acute pain 15. regular participation in high intensity athletic/sporting activities 16. sedentary lifestyle 17. currently pregnant 18. current cigarette smoker 19. on-going litigation associated with back pain 20. inability to walk independently without external support (e.g. walker). 21. regular participation in meditation techniques or training in mindfulness-based stress reduction

Keywords: mindfulness exercise meditation back pain
per-oral endoscopic myotomy (poem) for the treatment of achalasia, database repository

Conditions: Achalasia

Summary: poem (per-oral endoscopic myotomy (creating a muscle \[esophagus\] opening), an incision-less (no cutting of the surface of the body) endoscopic procedure, is an effective non-surgical alternative to release the muscle \& sphincter of the les for the treatment of achalasia.

achalasia is a disease of the muscle of the esophagus (food tube) \& means "a failure to relax." the esophagus consists of 3 parts: the first part (uppermost part) is the upper esophageal sphincter (ues). the ues is a specialized ring of muscle which separates the esophagus from the throat, \& prevents food in the second part (body) of the esophagus from regurgitating into the throat. the third part of the esophagus (lower esophageal sphincter \[les\]) also consists of a specialized ring of muscle which separates the body of the esophagus from the stomach, \& prevents food \& acid from regurgitating into the body of the esophagus. when achalasia is present, patients experience dysphasia (difficulty swallowing food, \& \[sometimes\] liquids), chest pain \& can experience recurrent pneumonia \& loss of weight. current treatments for achalasia include oral medications (calcium channel blockers) to relax the les (difficult to swallow pill/capsule), dilation (stretching) of the les, (temporary relief) \& esophagomyotomy (general surgery to cut the les). poem (per-oral endoscopic myotomy (creating a muscle \[esophagus\] opening), an incision-less (no cutting of the surface of the body) endoscopic procedure, is an effective non-surgical alternative to release the muscle \& sphincter of the les for the treatment of achalasia.

Eligibility criteria:
inclusion criteria: 18 years of age referral for the treatment of achalasia exclusion criteria: less than 18 years of age; absence of achalasia

Keywords: achalasia
predictor of residual neuromuscular blockade in recovery room after general anesthesia

Conditions: Residual Neuromuscular Blockade

Summary: background when general anesthesia was performed, neuromuscular blocking agents (nmbas) are frequently used for facilitate tracheal intubation and keep patient still and relax during surgery. unfortunately, residual neuromuscular blockade are important complication. there are many factors that affect neuromuscular blockade and may prolong effect of nmbas which we already know about that such as body temperature, drugs, some kind of diseases. however there are no recent studies that mention about other factors. the purpose of this study is to find out other factors that affect nmbas effect to improve patient safety. methods the study is a prospective, non-randomized, blinded, observational study. 222 patients will be included in this study and will be performed general anesthesia. anesthetic technique and agent which are used depend on regular staff. information of patient will be collected are age, sex, weight, height, asa classification, anesthetic technique, anesthetic and surgical time, amount of inhalation agent, amount of nmbas, amount of opioids and reversal agents. after anesthesia finish, patient will be brought to recovery room and train of four watch® will be placed and record train of four ratio by this research staff. train of four ratio \< 0.9 will be defined as there is residual neuromuscular blockade in this patient. all patients will be divided into 2 groups: residual blockade group(patient who have train of four \ 0.9). all factor of each group will be compared between. statistical will be analyzed to find significant factor which affect neuromuscular blockade.

study about residual neuromuscular blockade

Eligibility criteria:
inclusion criteria: * - age ≥ 18 years * american society of anesthesiologist class i-iii * patient who are schedule for intraabdominal surgery, orthopedic surgery and gynecologic surgery under general anesthesia and use neuromuscular blocking agents (nmbas) exclusion criteria: * - patients who have myasthenia gravis, myotonia, muscular dystrophy, upper motor neuron lesion * patients who have drug which influence neuromuscular action such as oral muscle relaxant, anticonvulsants, magnesium sulfate * body temperature \>37.8 or \< 36 degree celsius before operation

Keywords: residual neuromuscular blockade
bioequivalence study of pantoprazole 40 mg dr tablets and protonix 40 mg tablets under fed conditions

Conditions: Healthy

Summary: the objective of this study was to assess the single-dose bioequivalence of kudco's and wyeth pharmaceuticals' (protonix) 40 mg pantoprazole sodium delayed-lease tablets, under fed conditions.

this was an open-label, randomized, fully replicated crossover, 2-sequence bioequivalence study under fed conditions.

Eligibility criteria:
inclusion criteria: * healthy, adult, non-smoking (for at least 6 months) male or female volunteers, 18 - 55 years of age. * weighed at least 52 kg for males and 45 kg for females and within 15% of their ideal weights (table of "desirable weights of adults", metropolitan life insurance company, 1983). * medically healthy subjects with clinically normal laboratory profiles, vital signs, and ecg. * females of childbearing potential were either sexually inactive (abstinent) for 14 days prior to the first dose and throughout the study, or using one of the following acceptable birth control methods: 1. surgically sterile (bilateral tubal ligation, hysterectomy, bilateral oophorectomy) 6 months minimum. 2. intrauterine device (iud) in place for at least 3 months. 3. barrier method (condom, diaphragm) with spermicide for at least 14 days prior to the first dose and throughout the study. 4. surgical sterilization of the partner (vasectomy for 6 months minimum). 5. hormonal contraceptives for at least 3 months prior to the first dose of the study. * gave voluntary written informed consent to participate in the study. exclusion criteria: * history or presence of significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease. * in addition, history or presence of: 1. alcoholism or drug abuse within the past 2 years; 2. hypersensitivity or idiosyncratic reaction to pantoprazole, omeprazole, or any other substituted benzimidazole proton-pump. inhibitors. * females who were pregnant or lactating. * history of tobacco use or use of products containing nicotine (i.e., smoking cessation aids such as nicotine gum or patches) within the 6 months prior to the first dose. * subjects who tested positive at screening for human immunodeficiency virus (hiv) antibody screen, hepatitis b surface antigen screen (hbsag), or hepatitis c antibody screen (hcv). * treatment with any known enzyme-altering drugs (barbiturates, phenothiazines, cimetidine, etc.) within 30 days prior to the first dose. * difficulty in swallowing medication or any gastrointestinal disease that would affect the drug absorption. * subjects who had been on a special diet (for whatever reason) during the 28 days prior to the first dose and throughout the study. * subjects who, through completion of the study, would have donated in excess of: * 500 ml of blood in 14 days; * 1500 ml of blood in 180 days; * 2500 ml of blood in one years. * subjects who participated in another clinical trial with 28 days prior to the first dose.

Keywords: single dose crossover be study
magnetic resonance imaging for lymph node staging in ovarian cancer

Conditions: Ovarian Neoplasms

Summary: advanced epithelial ovarian cancer has high morbidity and mortality. patients presenting with advanced stage ovarian cancer often have cancer spread to regional lymph nodes. imaging strategies to depict involved lymph nodes are currently not successful. the purpose of this study is to evaluate if magnetic resonance imaging (mri) with gadofosveset trisodium contrast enhancement (gdf-mri) and diffusion weighted imaging (dw-mri) is able to identify involved lymph nodes in a preoperative setting. this could guide the surgeon during surgery to dissect lymph nodes which could lead to an optimal diagnosis/staging with the lowest possible morbidity. we want to determine the optimal imaging settings and feasibility of mri for the detection of pathological lymph nodes in women with advanced (figo stage iib-iv) ovarian cancer undergoing primary debulking surgery and compare this to conventional imaging with computer tomography (ct).


Eligibility criteria:
inclusion criteria: * non-pregnant female * expected figo stage iib-iv epithelial ovarian carcinoma * scheduled for primary debulking surgery * written informed consent * at least 18 years of age. exclusion criteria: * patients estimated to have more benefit from neoadjuvant chemotherapy * ineligibility to undergo mri * non-mr compatible metallic implants or foreign bodies (ferromagnetic aneurysm clip, pacemaker, neurostimulation system, etcetera). * claustrophobia * ineligibility to receive gadofosveset contrast (history of contrast allergy, * history of a prior allergic reaction to the active substance or to any of the excipients of ablavar™. * impaired kidney function (glomerular filtration rate \<30 ml/min/1.73m2). * previous para-aortic or pelvic lymphadenectomy * history of a malignant tumour. * pregnant or lactating patients. incapacitated subjects

Keywords: magnetic resonance imaging gadofosveset trisodium nodal imaging
study of denosumab vs. zoledronic acid to treat bone metastases in subjects with advanced cancer or multiple myeloma.

Conditions: Bone Metastases

Summary: the purpose of this study is to determine if denosumab is non-inferior to zoledronic acid (zometa®) in the treatment of bone metastases (lytic bone lesions from multiple myeloma) in subjects with advanced cancer and multiple myeloma (excluding breast and prostate cancer)


Eligibility criteria:
inclusion criteria: * adults with histologically/cystologically confirmed advanced cancers including solid tumors, multiple myeloma, and lymphoma * radiographic evidence of at least one bone metastasis (or lytic bone lesion from multiple myeloma); ecog performance status 0, 1, or 2 * adequate organ function exclusion criteria: * diagnosis of breast or prostate cancer * current or prior intravenous bisphosphonate administration * current or prior oral bisphosphonates for bone metastases, life expectancy of less than 6 months * prior history or current evidence of osteonecrosis/osteomyelitis of the jaw

Keywords: bone metastases lytic bone lesions advanced cancer multiple myeloma lymphoma solid tumors skeletal related events skeletal fractures spinal cord compressions, radiation to bone surgery to bone, bisphosphonates denosumab
implantable loop recorder versus conventional ambulatory monitoring in detecting atrial fibrillation after pulmonary vein isolation

Conditions: Atrial Fibrillation

Summary: the primary aim of the study is to assess the efficacy of continuous rhythm monitoring with an implantable loop recorder (ilr) compared to conventional ambulatory electrocardiography in detecting episodes of atrial fibrillation after pulmonary vein isolation (pvi). the secondary aim is to assess the efficacy of pvi during a two years follow-up and to assess the reliability of the implantable loop recorder in detecting atrial fibrillation. 50 patients will be enrolled into the study. after enrollment an implantable loop recorder will be implanted at least 6 weeks before scheduled pvi. all patients will be followed for 24 months after pvi. during the follow-up period a 72-hours ambulatory electrocardiographic monitoring will be performed at 1, 6, 12, 18, and 24 months. transthoracic echocardiography will be performed at enrollment, 3, 12, and 24 months after pvi. moreover, quality of life will be assessed at baseline, and 6 and 12 months after pvi.


Eligibility criteria:
inclusion criteria: * age =\> 30 to =\< 70 years * documentation of paroxysmal atrial fibrillation * documentation of persistent atrial fibrillation of \< 3 months duration termination either spontaneously or by dc cardioversion * scheduled pulmonary vein isolation * treatment with at least one class ic or class iii antiarrhythmic drug tried exclusion criteria: * atrial fibrillation episodes \> 3 months or permanent atrial fibrillation * no indication for pulmonary vein isolation * contraindications for anticoagulation treatment * no informed consent

Keywords: atrial fibrillation monitoring pulmonary vein isolation implantable loop recorder
prevalence of pulmonary arterial hypertension in patients with connective tissue diseases in egyptian patients

Conditions: Connective Tissue Diseases; Pulmonary Hypertension

Summary: * measuring the incidence and prevalence of pah in egyptian patients with different types of mcd * determination of survival \& the risk factors of mortality.

ph is defined as a mean pulmonary artery pressure greater than 25 mmhg. pah can be assessed by different means, however right heart catheterization (rhc) is the gold standard diagnostic method . among the different subgroups of pulmonary arterial hypertension (pah), those associated with connective tissue diseases (ctds) are a specific entity with distinct hemodynamic and prognostic features reflecting the importance of a rheumatological assessment in pah, especially with the unfavorable prognostic impact in these patients. compared to patients with idiopathic pah, patients with ctd-associated pah have a higher mortality and a lower walking distance on the 6-minute walk test, higher levels of b-type natriuretic peptide, worse right ventricular function, more left-sided heart dysfunction, lower lung function, and more pericardial disease. that's why, pah screening is routinely performed in systemic sclerosis (ssc) and in other ctds and also, as suggested by international guidelines, it is important to rule out ctds in patients with pah, because patients diagnosed as idiopathic pah (ipah) may have an associated ctd previously unrecognized. although the similarities in pathogenesis of pah in ctd such as systemic sclerosis (ssc), systemic lupus erythematosus (sle), and mixed connective tissue disease (mctd), there are variabilities in outcomes in patients with ctd-associated pah.

Eligibility criteria:
inclusion criteria: - patients diagnosed as connective tissue diseases fulfilling acr criteria will be recruited exclusion criteria: non -
outpatient management of tonsillectomy in adults

Conditions: Tonsillectomy; Pain; Ambulatory

Summary: tonsillectomy is a frequent surgical procedure in the ent specialty but it can be a source of postoperative pain that can be important. these pains complicate the intake of food and in particular the intake of analgesic drugs per os and require the prolongation of the hospitalization in order to continue an intravenous analgesia. the aim is to set up a protocol for ambulatory care of adult tonsillectomies. then, it would allow an improvement of the postoperative quality of life for the patient, who prefers a quicker return home.the study aims to allow patients to come back home early after tonsillectomies with intravenous analgesia. pain, feeding and quality of life will be evaluated regularly through an application called maela during a few days after surgery. they will also be evaluated by nurses coming via providers.


Eligibility criteria:
inclusion criteria: * indication for a tonsillectomy defined in the french recommendations * age between 18 and 60 yo * providing free and informed consent to participate * having a smartphone able to process maela application * affiliation to french social security

Keywords: tonsillectomy pain ambulatory
intracameral moxifloxacin for prevention of postcataract endophthalmitis

Conditions: Endophthalmitis

Summary: the aim of this study was to evaluate the efficacy and safety of the prophylactic effect of intracameral moxifloxacin for prevention of postcataract endophthalmitis.

although cataract surgery is generally considered a safe procedure resulting in a favourable visual outcome, surgical complications do occur. the most feared complication is postoperative endophthalmitis which is an infectious condition caused by micro-organisms introduced to the interior of the eye during or after the surgical procedure. as endophthalmitis is an infection, it should be preventable by antibiotic treatment. prophylactic antibiotic treatment can be given as topical treatment preoperatively, or during surgery directly into the anterior chamber, or as a subconjunctival, or it can be given as topical treatment postoperatively. the aim of this study was to evaluate the efficacy and safety of the prophylactic effect of intracameral moxifloxacin for prevention of postcataract endophthalmitis.

Eligibility criteria:
inclusion criteria: * diagnosis of visually significant cataract exclusion criteria: * has known allergies to moxifloxacin * has significant ocular co-morbidities in one or both eyes which may include (but is not limited to): advanced glaucoma, advanced or active macular degeneration, fuchs corneal dystrophy, prior corneal transplantation, advanced diabetic eye disease, history of retinal detachment or any patient that would require billing a complex cataract procedure for any reason * has a known history of a condition which causes an immuno-compromised host state

Keywords: endophthalmitis antibiotic therapy cataract surgery prevention